Paper Details

  1. Home
  2. Paper Details

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

Author: CamidgeD Ross, DoebeleRobert C, Kiseljak-VassiliadesKatja, OtonAna B, RothmanMicol S, Salian-MehtaSmita, WeickhardtAndrew J, WiermanMargaret E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Crizotinib therapy caused rapid suppression of T levels in men. The current results indicated that the site of action must include a central (hypothalamic or pituitary) effect, but additional direct testicular effects could not be excluded.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The objective of this study was to document the differences in testosterone (T) levels between crizotinib-treated and noncrizotinib-treated patients with metastatic nonsmall cell lung cancer (NSCLC). METHODS: Testosterone levels were measured in 19 men with metastatic NSCLC who received...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.27450

データ提供：米国国立医学図書館（NLM）

Rapid-Onset Hypogonadism Secondary to Crizotinib Use in Men with Metastatic Nonsmall Cell Lung Cancer

The study of cancer treatments is a complex and challenging field, with researchers constantly seeking to improve the effectiveness and safety of therapies. This study focuses on a specific drug called crizotinib, used to treat metastatic nonsmall cell lung cancer. The researchers aimed to investigate a potential side effect of crizotinib, namely rapid-onset hypogonadism, a condition characterized by low testosterone levels.

Navigating the Desert of Cancer Treatments

The study revealed a strong association between crizotinib therapy and rapid suppression of testosterone levels in men with metastatic nonsmall cell lung cancer. This finding raises concerns about the potential impact of crizotinib on male reproductive health. The researchers also suggest that crizotinib might be affecting the hypothalamus or pituitary gland, which play a key role in regulating testosterone production.

Navigating the Desert of Hormone Regulation

This research highlights the importance of closely monitoring testosterone levels in men receiving crizotinib therapy. The findings underscore the need for further research to fully understand the mechanisms behind crizotinib-induced hypogonadism and to develop strategies to mitigate this side effect.

Dr.Camel's Conclusion

This research provides crucial information about a potential side effect of crizotinib therapy in men with metastatic nonsmall cell lung cancer. The study's findings underscore the importance of careful monitoring and further research to understand the mechanisms behind crizotinib-induced hypogonadism. This knowledge is essential for optimizing the safety and effectiveness of crizotinib treatment, ensuring that patients receive the best possible care while minimizing potential risks.

Date :
  1. Date Completed 2013-01-31
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

22488744

DOI: Digital Object Identifier

10.1002/cncr.27450

Related Literature

Article Analysis
・Side Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.